Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Capecitabine + HX008 + Oxaliplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capecitabine||Xeloda||R340||Chemotherapy - Antimetabolite 13||Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).|
|HX008||HX-008|HX 008|Pucotenlimab||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 79||HX008 is a monoclonal antibody that binds to PD-1 (PDCD1) andblocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), blocking downstream signaling and potentially leading to activation of T-cell-mediated immune response against tumor cells and inhibition of tumor growth (PMID: 32106752).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 7||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|